

Proposal to expand AroCell's Board of Directors at the 2021 Annual General Meeting

The Nomination Committee proposes that AroCell's Board of Directors be expanded with one additional member at the 2021 Annual General Meeting through the election of Dr. Lotta Ljungqvist.

Dr. Ljungqvist is CEO of Testa Center at Cytiva. She is also a board member of Genovis AB, Vinnova, SciLifeLab, Atlas Antibodies AB and SwedenBio. Previously she was head of R&D BioProcess GE Life Sciences at GE Healthcare. She holds a Ph.D. in Biochemistry from the Royal Institute of Technology in Stockholm. During 2007/2008 she was CEO of IMEA AB, a biotech company dedicated to developing Biopharmaceuticals. Prior to that, Dr. Ljungqvist headed a Biopharmaceutical Contract Manufacturing Organization in Biovitrum during 2001-2007. Other positions include project management positions with Pharmacia Corp and Pharmacia & Upjohn.

The proposed new Board of Directors to the AGM is as follows: Re-election of Claes Post, Agneta Franksson, Eva Nordström and Karin Eriksson-Widblom and new election of Lotta Ljungqvist.

The Nomination Committee proposes re-election of Claes Post as Chairman of the Board.

AroCells Nomination Committee consists of:

Jon Eiken (Chairman)
Mikael Lönn
Bernhard Tribukait
Claes Post

Contacts

Anders Hultman, CEO
Phone: +46(0)18 50 30 20
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments

[Proposal to expand AroCell's Board of Directors at the 2021 Annual General Meeting](#)